<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03405597</url>
  </required_header>
  <id_info>
    <org_study_id>13/2560(EC1)</org_study_id>
    <nct_id>NCT03405597</nct_id>
  </id_info>
  <brief_title>HBsAb Response After HBV Vaccination in Chronic Hepatitis B Patients Who Have Lost HBsAg</brief_title>
  <official_title>HBsAb Response After HBV Vaccination in Chronic Hepatitis B Patients Who Have Lost HBsAg</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic HBV infection is major problem in Asian countries. Years after chronic infection, in
      some cases serum HBsAg level declines to unmeasurable level. Some of patients develop
      anti-HBsAb but there is no standard treatment to accelerate HBsAg seroconversion.

      There is a study to determine efficacy and safety of HBV vaccine in who is Chronic HBV
      infection and lost their HBsAg without seroconversion to anti-HBsAb.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 30, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HBsAb level at 4 weeks after complete vaccine injection</measure>
    <time_frame>an average of 7 months</time_frame>
    <description>HBsAb level more than 10 mIU/ml at 7 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HBsAb level at 6 months after complete vaccine injection</measure>
    <time_frame>an average of 1 year</time_frame>
    <description>HBsAb level more than 10 mIU/ml at 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event from HBV vaccine</measure>
    <time_frame>an average of 1 year</time_frame>
    <description>Any adverse event from HBV vaccine by CTCAE v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Factors associated with HBV vaccine response</measure>
    <time_frame>an average of 1 year</time_frame>
    <description>Factors associated with HBV vaccine response at 12 months</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">97</enrollment>
  <condition>Chronic Hepatitis B, HBsAg, Hepatitis B Vaccine</condition>
  <arm_group>
    <arm_group_label>Healthy control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Commercial Hepatitis B vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chronic hepatitis B with vaccination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Commercial Hepatitis B vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chronic hepatitis B without vaccination</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Commercial Hepatitis B vaccine</intervention_name>
    <description>Commercial Hepatitis B vaccine (Engerix B) 20 microgram subcutaneous injection at month 0, 1, 6</description>
    <arm_group_label>Healthy control</arm_group_label>
    <arm_group_label>Chronic hepatitis B with vaccination</arm_group_label>
    <other_name>Engerix B</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard Treatment</intervention_name>
    <description>HBsAg, HBsAb test Ultrasound upper abdomen every 6 months</description>
    <arm_group_label>Chronic hepatitis B with vaccination</arm_group_label>
    <arm_group_label>Chronic hepatitis B without vaccination</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Chronic Hepatitis B infection group

          -  18-80 year-old

          -  Compensated liver disease

          -  Chronic HBV infection with or without NUCs treatment

          -  History of HBsAg positive &gt; 6 months

          -  HBsAg negative with qualitative Elecsys (Roche) twice at least 6 months apart

          -  HBsAb negative

          -  HBV DNA &lt; 20 IU/mL

        Healthy group

          -  Healthy person without history of HBV vaccination (HBsAg, anti-HBc and HBsAb negative)

        Exclusion Criteria:

          -  History of previous HBV vaccination

          -  Anti-HCV and/or anti-HIV positive

          -  Decompensated cirrhosis

          -  History of previous malignancies

          -  History or currently receive immunotherapy, cytotoxic or immunosuppressive agents

          -  Patient with immunodeficiency disease

          -  Creatinine &gt; 1.5 mg/dL

          -  Pregnancy or lactating woman

          -  Unable to consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tawesak Tanwandee</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Medicine, Faculty of medicine Siriraj Hospital, Mahidol University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Suppawat Jiraphairot</last_name>
    <phone>+66 877116517</phone>
    <email>suppawat_tu@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tawesak Tanwandee</last_name>
    <phone>+66 24197281</phone>
    <phone_ext>102</phone_ext>
    <email>tawesak@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Faculty of Medicine Siriraj Hospital</name>
      <address>
        <city>Bangkoknoi</city>
        <state>Bangkok</state>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chairat Shayakul</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <reference>
    <citation>Taheri H, Hasanjani Roushan MR, Soleimani Amiri MJ, Pouralijan M, Bijani A. Efficacy of Hepatitis B vaccine in those who lost Hepatitis B surface antigen during follow-up: Efficacy of HBV vaccine in those who lost HBsAg. Hepat Mon. 2011 Feb;11(2):119-22.</citation>
    <PMID>22087128</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2018</study_first_submitted>
  <study_first_submitted_qc>January 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2018</study_first_posted>
  <last_update_submitted>January 12, 2018</last_update_submitted>
  <last_update_submitted_qc>January 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

